Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors di Joseph Toker (15399882)

Soggetti:

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors di Kristoffer Staal Rohrberg (15009138)

Soggetti:

Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization di Matthia A. Karreman (15097355)

Soggetti:

Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization di Matthia A. Karreman (15097355)

Soggetti:

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4⁺ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance di Ankita Mitra (17141783)

Soggetti:

Figure S4 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma di Dahihm Kim (16546203)

Soggetti:

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4⁺ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance di Ankita Mitra (17141783)

Soggetti:

Figure S5 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma di Dahihm Kim (16546203)

Soggetti:

Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization di Matthia A. Karreman (15097355)

Soggetti:

Supplementary Data from Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization di Matthia A. Karreman (15097355)

Soggetti:

Table S1 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma di Dahihm Kim (16546203)

Soggetti:

Figure S1 from Ccr2⁺ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma di Dahihm Kim (16546203)

Soggetti: